Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP 21 versus KIMIDESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP 21 versus KIMIDESS.
ESTROSTEP 21 vs KIMIDESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
5 mg orally once daily, with or without food.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive